Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorcaserin - Eisai Inc

Drug Profile

Lorcaserin - Eisai Inc

Alternative Names: APD-356; Belviq; Belviq XR; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin hydrochloride; Venespri

Latest Information Update: 27 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; CY Biotech; Eisai Inc; Ildong Pharmaceutical
  • Class Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • Discontinued Smoking withdrawal

Most Recent Events

  • 26 Feb 2019 The USFDA accepts sNDA to update the label for BELVIQ® (lorcaserin HCl) CIV 10mg twice-daily and/or BELVIQ XR (lorcaserin HCl) CIV once daily
  • 16 Oct 2018 Eisai grants development and marketing rights to Eurofarma of lorcaserin for Obesity in 17 countries of Latin America and Carribean
  • 05 Oct 2018 Updated adverse events data from the phase III/IV CAMELLIA-TIMI 61 trial in Obesity presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top